GILD vs LAB · P/E 18, rev $29.44B vs rev $174.4M
Gilead Sciences Inc (GILD) versus Standard Biotools Inc (LAB) — a side-by-side from cached financials, not a winner call.
Gilead Sciences Inc (GILD) is a drug manufacturers - general company listed on US.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
Latest reported GILD revenue for 2025-12-31 was $29.44B. Net income was $8.51B. Revenue was up 2.4% from 2024-12-31 to 2025-12-31. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
GILD currently screens at market cap $160.15B and trailing P/E 17.5. LAB currently screens at market cap $317.1M.
Not investment advice. Open the GILD and LAB stock pages for the full models.
Not investment advice.